Navigation Links
Nile Therapeutics Reports 2012 Second Quarter Financial Results
Date:8/14/2012

SAN FRANCISCO, Aug. 14, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX.PK), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its second quarter financial results for 2012. 

For the second quarter of 2012, Nile reported a net operating loss of $0.3 million, or $0.01 per share, compared to a net loss of approximately $0.9 million, or $0.03 per share during the second quarter of 2011. Weighted-average shares outstanding for the quarter were 43 million.

Net cash used in operating activities in the second quarter of 2012 was approximately $0.9 million. As of June 30, 2012, Nile had cash and cash equivalents of $0.8 million compared to $1.0 million as of December 31, 2011.About Nile TherapeuticsNile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's plans to develop cenderitide in the post-acute setting and the anticipated benefits of cenderitide for patients in the post-acute setting are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include Nile's immediate need to raise additional capital to fund its general corporate activities and its need to raise substantial additional capital to fund its planned Phase 2 study of cenderitide and to otherwise fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2011 filed with the Securities and Exchange Commission on April 2, 2012. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

 Condensed Statement of OperationsThree months ended June 30,Six months ended June 30,2012201120122011Income:Grant income

$
-$
-$
-$
-Collaboration income

-346,000195,500346,000Total income

-346,000195,500346,000Operating expenses:Research and development

332,450702,930797,8031,325,262General and administrative

441,970523,305941,9901,098,583Total operating expenses

774,4201,226,2351,739,7932,423,845Loss from operations

(774,420)(880,235)(1,544,293)(2,077,845)Other income (expense):Interest income

5961,0468403,032Interest expense

----Other income (expense)

420,890(1,341)418,640(1,509)Total other income (expense) 

421,486(295)419,4801,523Net loss

$  (352,934)$  (880,530)$ (1,124,813)$ (2,076,322)Basic and diluted loss per share

$
(0.01)$
(0.03)$
(0.03)$
(0.06)Weighted-average common shares outstanding

42,951,79135,091,65341,332,01134,882,947 Summary Balance Sheet(in thousands)June 30,  2012December 31, 2011Cash and cash equivalents $
777$   1,039Working Capital$
75$
769Stockholders' equity$
542$
831 


'/>"/>
SOURCE Nile Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zenobia Therapeutics Announce A Partnership With The Alzheimers Drug Discovery Foundation
2. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
3. Echo Therapeutics Announces Second Quarter 2012 Financial Results
4. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
5. Echo Therapeutics Announces $20 Million Financing with Platinum-Montaur Life Sciences
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
8. Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
9. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
10. Silence Therapeutics - Admission of Shares and Board Update
11. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $3.5 billion ... and forecasts for all the given segments on global as well ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a ... an end-to-end supply chain management firm with expertise serving ... Product Solutions Rick Zaffarano was named a ... the Supply Chain by the only publication exclusively dedicated ... food supply chain. "Rick has brought to ...
(Date:3/23/2017)... SILVER SPRING, Md. , March 23, 2017 /PRNewswire-USNewswire/ ... approval to Bavencio (avelumab) for the treatment of adults ... Merkel cell carcinoma (MCC), including those who have not ... for metastatic MCC, a rare, aggressive form of skin ... the most common cancers, patients with a rare form ...
Breaking Medicine Technology:
(Date:3/24/2017)... Orion, MI (PRWEB) , ... March 24, 2017 ... ... insurance assistance, financial planning, and related services to families and business owners across ... initiative aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, Dr. ... for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, ... obstructive type, is increasingly being treated at dental offices with newly developed procedures ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
Breaking Medicine News(10 mins):